"ces pain, causes discomfort, significantly reduces the quality of life for the affected patient, and lacks specific and consensual instruments able to adequately assess its signs and symptoms. This article presents these needs that are still unmet in clinical practice and that relate to the tools currently available for the assessment of the therapeutic efficacy of drugs on the disease symptoms and signs. Suggestions are presented regarding new endpoints and tools to be used in further clinical trials designed to assess the effect of therapies on CVD, in particular studies with Daflon 500 m"

Full text